Depression Clinical Trial
Official title:
Mobile Mindfulness to Improve Psychological Distress After Critical Illness
Verified date | January 2018 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Many survivors of the intensive care unit (ICU) suffer from persistent symptoms of depression, anxiety, and post-traumatic stress disorder (PTSD). In this study, the investigators will test the impact of mindfulness to address this distress.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 5, 2017 |
Est. primary completion date | May 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria (the investigators will target patients at high risk for psychological
distress): - age =18 years - acute cardiorespiratory failure managed in an intensive care unit - reside at home before hospital admission (i.e., not in a facility) - Respiratory failure, =1 of these: - mechanical ventilation via endotracheal tube for = 12 hours - non-invasive ventilation (CPAP, BiPAP) for > 4 hours in a 24 hour period provided for acute respiratory failure in an ICU (not for obstructive sleep apnea or other stable use) - high flow nasal cannula or face mask O2 with FiO2 = 0.5 for =4 hours - Cardiac / circulatory failure, =1 of these: - use of vasopressors for shock of any etiology for > 1 hour - use of inotropes for shock of any etiology for > 1 hour - use of aortic balloon pump for cardiogenic shock Exclusion Criteria (present before consent): Patients will be excluded if they have characteristics that would prohibit adequate participation including: - pre-existing significant cognitive impairment (e.g., dementia) - treated for severe or unstable mental illness within 6 months preceding current admission (e.g., depression with psychosis, suicidality, schizophrenia as per medical record) - hospital inpatient within 3 months before current admission - active substance abuse at the time of admission - lack of decisional capacity [*'Decisional capacity' is defined as the ability to participate in effective decision making and provide informed consent. That is, in the judgment of the examiner, the patient, after reading the IRB approved patient consent document (or having it read to them) can (a) generally understand the terms of participation in the study: the purpose of the study, what will be required of study participants; the potential risks, benefits and alternatives of study participation; pros & cons of study involvement and (b) can communicate a choice in his/her own words (or write on a communication board)] - current significant cognitive impairment (=3 errors on the Callahan cognitive status screen; see below) - need for a translator because of poor English fluency [many study instruments are not validated in other languages] - expected survival <6 months per attending physician - ICU length of stay >30 days - lack of either: - reliable or sufficient smartphone with cellular data plan or - reliable computer online access plus telephone access - unable to complete study procedures as determined by study staff - discharge to a location other than a home setting - complex medical care expected soon after discharge (e.g., multiple planned surgeries, transplantation evaluation (including outpatient daily cardiopulmonary rehabilitation), extensive travel needs for hemodialysis, disruptive chemotherapy or XRT regimen, etc) Other issues relevant to the consent process: - unable to approach patient for logistical reasons (e.g., off ward in test at time of approach, etc) - patient discharged before consent could be obtained - patient dies before consent obtained Patient exclusion criteria present after consent but before randomization: After providing informed consent, patients will become ineligible if any of the following are present: - they become too ill to participate (or die) - they exhibit significant cognitive disability - they exhibit suicidality - patient was unexpectedly discharged to location other than a home setting and then did not arrive home within 1 month from hospital discharge |
Country | Name | City | State |
---|---|---|---|
United States | Duke University | Durham | North Carolina |
United States | University of Washington | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Center for Complementary and Integrative Health (NCCIH), University of Pennsylvania, University of Washington |
United States,
Cox CE, Porter LS, Buck PJ, Hoffa M, Jones D, Walton B, Hough CL, Greeson JM. Development and preliminary evaluation of a telephone-based mindfulness training intervention for survivors of critical illness. Ann Am Thorac Soc. 2014 Feb;11(2):173-81. doi: 10.1513/AnnalsATS.201308-283OC. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Usability Themes Developed From Semi-structured Participant Interviews | A usability measure. Open-ended feedback questions will be arranged in themes. | end of study | |
Primary | Percent of Eligible Participants Who Provided Consent | Percent of eligible participants who provided consent. Because this includes eligible yet not-as-yet randomized participants, there are no study arm differences analyzed. This is a feasibility measure. Target is 70%. | pre-randomization | |
Primary | Percent of Eligible Participants Who Provide Informed Consent and Were Randomized | Percent of eligible participants who provide informed consent and were randomized. A measure of feasibility. Target is 60%. | randomization | |
Primary | Client Satisfaction Questionnaire (CSQ) Score | Acceptability was measured with the adapted Client Satisfaction Questionnaire (CSQ), which assesses credibility and satisfaction (range 9 [low, a worse outcome] to 36 [highest, a better outcome]). Target is mean score >10. | 1 month post-randomization | |
Primary | System Usability Scale (SUS) | Usability of the mobile app was assessed with open-ended participant feedback and with the 10-item System Usability Scale (SUS; 0 [lowest] to 100 [highest]). A SUS score above a 68 would be considered above average and anything below 68 is below average. | 1 month post-randomization | |
Primary | Percent of Randomized Participants Who Drop Out of Study | A feasibility measure. Target is 20% or less. | baseline, end of study (approx. 4 months) | |
Primary | Percent of Participants Who Have Neither Dropped Out Nor Died Who Complete Telephone Interviews | Percent of participants who have neither dropped out nor died who complete telephone interviews. A feasibility measure. Target is 75%. | baseline, end of study (approx. 4 months) | |
Primary | Percent of Participants in the Self-directed MBT Group Who Complete Weekly Surveys | A feasibility measure. Target is 60%. Note that this is for completion of ALL FOUR weekly surveys. | baseline, end of study (approx. 4 months) | |
Primary | Percentage of Self-directed MBT Sessions Attended by Eligible Participants | A feasibility measure. Target is 50% among those who neither dropped out nor died. | baseline, end of study (approx. 4 months) | |
Primary | Visual Analog Satisfaction Scale | A measure of acceptability of the intervention. Target mean score is 75% or greater. | after intervention completion, up to 8 weeks post-randomization | |
Primary | Number of Participant Clicks on Study Website | A usability measure obtained using Google Analytics. | baseline, end of study (approx. 4 months) | |
Secondary | Change in Psychological Distress Symptoms as Measured by the Patient Health Questionnaire (PHQ) Scale | Depression symptoms were assessed with the PHQ-9, a 9-item scale (range 0 [no distress] to 27 [high distress]); symptom severity is interpreted as mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27). | Between randomization and 3 months post-randomization | |
Secondary | Change in Distress Associated With Physical Symptoms | The PHQ-10 (Patient Health Questionnaire) was used to measure distress associated with physical symptoms (range 0 [none] to 30 [very troublesome]). | Between randomization and 3 months post-randomization | |
Secondary | Change in Mindfulness Skills | Mindfulness skills were measured with the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R), a 12-item measure of mindful qualities (range 12 [low ability] to 48 [highest ability]). | Between randomization and 3 months post-randomization | |
Secondary | Change in Psychological Distress Symptoms as Measured by the GAD-7 | Anxiety symptoms were measured using the Generalized Anxiety Disorder 7-item scale (GAD-7; range 0 [no distress] to 21 [high distress]); symptom severity is interpreted as mild (5-9), moderate (10-14), and severe (15-21). | Between randomization and 3 months post-randomization | |
Secondary | Change in Psychological Distress Symptoms as Measured by the PTSS | The Post Traumatic Stress Scale (PTSS), a 10-item scale (range 10 [no symptoms] to 70 [high burden of symptoms]), was used to assess PTSD symptoms; >20 represents clinically important symptoms. | Between randomization and 3 months post-randomization | |
Secondary | Change in the Avoidance Domain of the Brief COPE Scale | Coping skills were measured with the Brief COPE scale (range 10 [low use] to 40 [highest use]). The Brief COPE is a self-report questionnaire used to assess a number of different coping behaviors and thoughts a person may have in response to a specific situation. | Between randomization and 3 months post-randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |